11 results · 23ms · Sources: EU EUDAMED, US FDA

Get notified when this changes

We'll email you when new records match this search — new devices, new clearances, certificate changes, or withdrawals.

Histolog® Scanner (Hardware 2.4, Software 3.3)

FDA 510(k)
FDA Class 2 ·Gastroenterology, Urology

SpheRx

FDA UDI
Nuvasive, Inc.·00887517443977·SpheRx® II Conn, 27.5mm Transverse Fixed

LCP

FDA UDI
Synthes GmbH·10886982166418·3.5MM LCP® POSTEROLATERAL DSTL HUMERUS PL-LAT S...

ENDOPHYS PRESSURE SENSING SHEATH KIT

FDA 510(k)
FDA Class 2 ·Cardiovascular

PROCERA ABUTMENT OCTAGON

FDA 510(k)
FDA Class 2 ·Dental

OT VERIO IQ METER

FDA Adverse Event
Malfunction ·LIFESCAN EUROPE, A DIVISION OF CILAG GMBH INTL·Product code NBW·November 18, 2015

HUDSON CIRCUIT, NEONATAL, DUAL HTD LUMB W/18 IN

FDA Adverse Event
Malfunction ·TELEFLEX MEDICAL·Product code CAI·August 19, 2011

RX VIATRAC 14 PLUS PERIPHERAL DILATATION CATHETER

FDA Adverse Event
Injury ·ABBOTT VASCULAR-VASCULAR SOLUTIONS·Product code LIT·November 21, 2008

HAKIM PROGRAMMABLE VALVE WITH PRECHAMBER

FDA Adverse Event
Injury ·CODMAN & SHURTLEFF, INC.·Product code JXG·July 22, 2013

MERIDIAN FILTER

FDA Adverse Event
Malfunction ·BARD PERIPHERAL VASCULAR, INC.·Product code DTK·October 21, 2019

Boston Scientific TELIGEN, Implantable Cardiac Defibrillator models E102, E110, the following models are not available in the US: models E103, E111, F102, F103, F110, F111. Sterilized using ethylene oxide. Product Usage: This family of implantable cardioverter defibrillators (ICDs) provide a variety of therapies including: -Ventricular tachyarrhythmia therapy, which is used to treat rhythms associated with sudden cardiac death such as VT and VF; -Bradycardia pacing, including adaptive rate pacing, to detect and treat bradyarrhythmias and to provide cardiac rate support after defibrillation therapy. Boston Scientific implantable cardioverter defibrillators (ICDs) are indicated to provide ventricular antitachycardia pacing (ATP) and ventricular defibrillation for automated treatment of life-threatening ventricular arrhythmias

FDA Enforcement
Class II ·Terminated·Boston Scientific CRM Corp·October 29, 2014